Latest Interventional radiology Stories

TORONTO, Jan. 31, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the European interventional cardiology market will barely grow through 2017. Procedure growth will average around one percent per year, while revenue growth will be less than that. The market will be just over $1 billion by 2017. There will be a few bright spots of growth, including bioresorbable stents and intravascular imaging....

Society of Interventional Radiology publishes guidelines that capture consensus on clinical practice of intra-arterial stroke revascularization, recommend national stroke outcomes registry The first outcome-based guidelines for interventional treatment of acute ischemic stroke—providing recommendations for rapid treatment—will benefit individuals suffering from brain attacks, often caused by artery-blocking blood clots. Representatives from the Society of Interventional Radiology and...

Society of Interventional Radiology publishes guidelines that capture consensus on clinical practice of intra-arterial stroke revascularization, recommend national stroke outcomes registry FAIRFAX, Va., Jan. 29, 2013 /PRNewswire-USNewswire/ -- The first outcome-based guidelines for interventional treatment of acute ischemic stroke--providing recommendations for rapid treatment--will benefit individuals suffering from brain attacks, often caused by artery-blocking blood clots....

[286 Pages Report] Contrast Media/Agents Market reports is a comprehensive review specifically for contrast media used in medical and radiological procedures comprising of market analysis by product, applications, technology and end-users. (PRWEB) January 25, 2013 According to a new market research report “Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium and Barium), By Technique (X-ray, CT, MRI, Cath Lab and Ultrasound) and By Application (Radiology,...

WEBSTER, Texas and LEIPZIG, Germany, Jan. 24, 2013 /PRNewswire/ -- At the Leipzig Interventional Course (LINC) in Leipzig, Germany, physicians from the United States and Europe presented data on their clinical experience with the IDEV Technologies Supera® stent. LINC is a meeting forum of global interdisciplinary physicians focusing on endovascular peripheral interventional treatments. Results on over 1,000 treated patients were compiled and presented, including findings from...

TORONTO, Jan. 23, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, increasing awareness and diagnosis of peripheral vascular disease (PVD) along with the introduction of improved next-generation devices will lead the United States peripheral vascular (PV) device market to grow strongly to reach $3.3 billion by 2017. (Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO ) Lower extremity...

The interventional oncologist now has the unique ability to view the post-treatment ablation zone, intra-procedurally. Miami Beach, FL (PRWEB) January 18, 2013 INTIO Inc. is introducing SyncVIEW™, a new feature of the 510(k) cleared ClearStart SVM™ (Segmentation and Volumetric Measurement system), at the Clinical Interventional Oncology (CIO) Symposium in Miami Beach, January 18-19, 2013. SyncVIEW™ provides the interventional oncologist the unique ability to view the segmented...

“Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) - Global Trends & Forecast to 2017” is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) January 11, 2013 The global contrast media market is broadly segmented into barium-based, iodinated and gadolinium-based...

CINCINNATI, Jan. 8, 2013 /PRNewswire/ -- A first-of-its-kind cardiac interventional device that dissolves after opening blocked arteries is being evaluated in a national research study led by clinical researchers at The Christ Hospital's Lindner Research Center. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/59645-the-christ-hospital-bioresorbable-scaffold-coronary-artery-disease Absorb(TM), the first drug-eluting, fully...

ABBOTT PARK, Ill., Jan. 8, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the initiation of the ABSORB III clinical trial in patients in the United States. This randomized, controlled trial is designed to enroll approximately 2,250 patients, the majority in the United States, and compare the performance of Abbott's drug eluting Absorb((TM)) Bioresorbable Vascular Scaffold (BVS) device to the company's XIENCE((TM)) family of drug eluting stents. The start of this trial in the...